Atherosclerosis (heart-disease) is due to formation of lipid-laden plaques in the arteries. These plaques typically express immunosuppressive signals which prevents their removal by immune system. Recently, researchers at University of Ottawa utilized PLGA (AP023) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles to deliver immunotargeting compounds to plaques. This research holds promise as a potential treatment for heart disease. Read more: Patel, Yukta, Shireesha Manturthi, Saras Tiwari, Esha Gahunia, Amandine Courtemanche, Michelle Gandelman, Marceline Côté, and Suresh Gadde. "Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy." ACS Pharmacology & Translational Science (2024). https://pubs.acs.org/doi/abs/10.1021/acsptsci.4c00292
“Atherosclerosis is a major contributor to cardiovascular diseases with a high global prevalence. It is characterized by the formation of lipid-laden plaques in the arteries, which eventually lead to plaque rupture and thrombosis. While the current lipid-lowering therapies are generally effective in lowering the risk of cardiovascular events, they do not address the underlying causes of disease. Defective resolution of inflammation and impaired efferocytosis are the main driving forces of atherosclerosis. Macrophages recognize cells for clearance by the expression of “eat me” and “do not eat me” signals, including the CD47-SIRPα axis. However, the “do not eat me” signal CD47 is overexpressed in atherosclerotic plaques, leading to compromised efferocytosis and secondary necrosis. In this context, prophagocytic antibodies have been explored to stimulate the clearance of apoptotic cells, but they are nonspecific and impact healthy tissues. In macrophages, downstream of signal regulatory protein α, lie protein tyrosine phosphatases, SHP 1/2, which can serve as effective targets for selectively phagocytosing apoptotic cells. While increasing the efferocytosis targets the end stages of lesion development, the underlying issue of inflammation still persists. Simultaneously increasing efferocytosis and reducing inflammation can be effective therapeutic strategies for managing atherosclerosis. For instance, IL-10 is a key anti-inflammatory mediator that enhances efferocytosis via phosphoSTAT3 (pSTAT3) activation. In this study, we developed a combination nanotherapy by encapsulating an SHP-1 inhibitor (NSC 87877) and IL-10 in a single nanoparticle platform [(S + IL)-NPs] to enhance efferocytosis and inflammation resolution. Our studies suggest that (S + IL)-NPs successfully encapsulated both agents, entered the macrophages, and delivered the agents into intracellular compartments. Additionally, (S + IL)-NPs decreased inflammation by suppressing pro-inflammatory markers and enhancing anti-inflammatory mediators. They also exhibited the potential for improved phagocytic activity via pSTAT3 activation. Our nanomedicine-mediated upregulation of the anti-inflammatory and efferocytic responses in macrophages shows promise for the treatment of atherosclerosis.”
PLGA-PEG-Mal (Cat# AP023): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP023#h
NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/
Video: https://youtu.be/2iOHeKrPL34
No comments:
Post a Comment